Companies › SAPU NANO (US)
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sapu003 mTOR inhibitor | MTOR | Phase 1 | Breast Cancer Metastatic | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07369505 | Sapu003 | Phase 1 | Breast Cancer Metastatic | Oncology | Dec 2026 |
iVascular S.L.U. Restorbio Faeth Therapeutics Celcuity Palvella Therapeutics Supernus Pharmaceuticals Eli Lilly AstraZeneca
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.